The role of Notch signaling pathway in metabolic bone disease
Yongguang Gao,Zhanda Fu,Junxia Guan,Xinhua Liu,Qing Zhang
DOI: https://doi.org/10.1016/j.bcp.2022.115377
IF: 6.1
2022-12-12
Biochemical Pharmacology
Abstract:Metabolic bone disease is the third most common endocrine disease after diabetes and thyroid diseases. More than 500 million people worldwide suffer from metabolic bone disease. The generation and development of bone metabolic diseases is a complex process regulated by multiple signaling pathways, among which the Notch signaling pathway is one of the most important pathways. The Notch signaling pathway regulates the differentiation and function of osteoblasts and osteoclasts, and affects the process of cartilage formation, bone formation and bone resorption. Genetic mutations in upstream and downstream of Notch signaling genes can lead to a series of metabolic bone diseases, such as Alagille syndrome, Adams-Oliver syndrome and spondylocostal dysostosis. In this review, we analyzed the mechanisms of Notch ligands, Notch receptors and signaling molecules in the process of signal transduction, and summarized the progress on the pathogenesis and clinical manifestations of bone metabolic diseases caused by Notch gene mutation. We hope to draw attention to the role of the Notch signaling pathway in metabolic bone diseases and provide new ideas and approaches for the diagnosis and treatment of metabolic bone diseases.
pharmacology & pharmacy
What problem does this paper attempt to address?